Sona NanotechSNANF 26 EBITDA Margin % is 0.00% as of Jan. 2026. GuruFocus rates SNANF with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 203 Medical Diagnostics & Research companies, Sona Nanotech ranks worse than 492610.34% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sona Nanotech's EBITDA for the
three
months ended in Jan. 2026 was $-0.34 Mil. Sona Nanotech's Revenue for the
three
months ended in Jan. 2026 was $0.00 Mil. Therefore, Sona Nanotech's EBITDA margin for the quarter that ended in Jan. 2026 was 0.00%.
Sona Nanotech (OTCPK:SNANF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sona Nanotech EBITDA Margin % Related Terms
Sona Nanotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sona Nanotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNANF vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Sona Nanotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sona Nanotech EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sona Nanotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sona Nanotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sona Nanotech (SNANF) has a EBITDA Margin % of 0.00% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sona Nanotech and its competitors. According to the industry distribution chart, Sona Nanotech ranks #999999 out of 203 companies in the Medical Diagnostics & Research industry.
Is Sona Nanotech's EBITDA Margin % too high?
Sona Nanotech's current EBITDA Margin % is 0.00%. Based on the distribution chart, Sona Nanotech ranks #999999 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sona Nanotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Sona Nanotech's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sona Nanotech ranks #999999 out of 203 companies for EBITDA Margin %. This places Sona Nanotech in the lower half of its industry. The industry median EBITDA Margin % is 5.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sona Nanotech and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sona Nanotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sona Nanotech stock overvalued right now?
Sona Nanotech (SNANF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Sona Nanotech's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sona Nanotech (SNANF), the current EBITDA Margin % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sona Nanotech Inc is involved in the nanotechnology life sciences industry. It has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles and is engaged in the research and development of its proprietary technology for use in biomedical applications and multiplex diagnostic testing platforms. The company is using its gold nano rods manufacturing technology to develop new products and methods for cancer treatment, including a Targeted Hyperthermia Therapy (THT). Additionally, it has filed patent applications in the U.S. regarding a gold nanorod conjugation concept for targeted drug delivery, combination therapies for treating cancer, and for an endoscope with an optical fibre and thermal sensor for photothermal therapy.
26GF Score
Get the complete analysis for SNANF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNANF has been successfully added to your 
